These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 30026012)

  • 41. Trends in the utilization of neoadjuvant therapy for pancreatic ductal adenocarcinoma.
    Brown ZJ; Cloyd JM
    J Surg Oncol; 2021 May; 123(6):1432-1440. PubMed ID: 33831253
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Microvascular invasion is a major prognostic factor after pancreatico-duodenectomy for adenocarcinoma.
    Panaro F; Kellil T; Vendrell J; Sega V; Souche R; Piardi T; Leon P; Cassinotto C; Assenat E; Rosso E; Navarro F
    J Surg Oncol; 2019 Sep; 120(3):483-493. PubMed ID: 31197842
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Respect - A multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer.
    Weniger M; Moir J; Damm M; Maggino L; Kordes M; Rosendahl J; Ceyhan GO; Schorn S;
    Pancreatology; 2020 Sep; 20(6):1131-1138. PubMed ID: 32739267
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
    Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP
    Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Patient outcome according to the 2017 international consensus on the definition of borderline resectable pancreatic ductal adenocarcinoma.
    Medrano J; Garnier J; Ewald J; Marchese U; Gilabert M; Launay S; Poizat F; Giovannini M; Delpero JR; Turrini O
    Pancreatology; 2020 Mar; 20(2):223-228. PubMed ID: 31839458
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Improvement in advanced pancreatic cancer survival with novel chemotherapeutic strategies - experience of a community based hospital.
    Hann A; Bohle W; Egger J; Zoller WG
    Z Gastroenterol; 2016 Oct; 54(10):1138-1142. PubMed ID: 27723905
    [No Abstract]   [Full Text] [Related]  

  • 47. Pancreatic cancer patients with lymph node involvement by direct tumor extension have similar survival to those with node-negative disease.
    Williams JL; Nguyen AH; Rochefort M; Muthusamy VR; Wainberg ZA; Dawson DW; Tomlinson JS; Hines OJ; Reber HA; Donahue TR
    J Surg Oncol; 2015 Sep; 112(4):396-402. PubMed ID: 26303811
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Survival impact based on hepatic artery lymph node status in pancreatic adenocarcinoma: A study of patients receiving modern chemotherapy.
    Perlmutter BC; Hossain MS; Naples R; Tu C; Vilchez V; McMichael J; Tullio K; Simon R; Walsh RM; Augustin T
    J Surg Oncol; 2021 Feb; 123(2):399-406. PubMed ID: 33159317
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CT response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after FOLFIRINOX.
    Tanaka M; Heckler M; Mihaljevic AL; Sun H; Klaiber U; Heger U; Büchler MW; Hackert T
    Eur J Surg Oncol; 2019 Aug; 45(8):1453-1459. PubMed ID: 30981446
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM).
    Trouilloud I; Dupont-Gossard AC; Malka D; Artru P; Gauthier M; Lecomte T; Aparicio T; Thirot-Bidault A; Lobry C; Asnacios A; Manet-Lacombe S; Fein F; Dubreuil O; Landi B; Zaanan A; Bonnetain F; Taïeb J
    Eur J Cancer; 2014 Dec; 50(18):3116-24. PubMed ID: 25454414
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The prognostic impact of para-aortic lymph node metastasis in pancreatic cancer: A systematic review and meta-analysis.
    Paiella S; Sandini M; Gianotti L; Butturini G; Salvia R; Bassi C
    Eur J Surg Oncol; 2016 May; 42(5):616-24. PubMed ID: 26916137
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma.
    Assaf E; Verlinde-Carvalho M; Delbaldo C; Grenier J; Sellam Z; Pouessel D; Bouaita L; Baumgaertner I; Sobhani I; Tayar C; Paul M; Culine S
    Oncology; 2011; 80(5-6):301-6. PubMed ID: 21778770
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
    Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P
    Oncology; 2015; 89(1):37-46. PubMed ID: 25766660
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Does the extent of lymphadenectomy have impact on the prognosis of patients with pancreatic cancer?
    Henne-Bruns D; Vogel I
    Onkologie; 2002 Feb; 25(1):69-71. PubMed ID: 11928695
    [No Abstract]   [Full Text] [Related]  

  • 55. Treatment landscape of metastatic pancreatic cancer.
    De Dosso S; Siebenhüner AR; Winder T; Meisel A; Fritsch R; Astaras C; Szturz P; Borner M
    Cancer Treat Rev; 2021 May; 96():102180. PubMed ID: 33812339
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pancreatic ductal adenocarcinoma: time for a neoadjuvant revolution?
    Salvia R; Malleo G; Maggino L; Milella M; Bassi C
    Updates Surg; 2020 Jun; 72(2):321-324. PubMed ID: 32445032
    [No Abstract]   [Full Text] [Related]  

  • 57. Neoadjuvant chemoradiation for non-metastatic pancreatic cancer increases margin-negative and node-negative rates at resection.
    Berriochoa CA; Abdel-Wahab M; Leyrer CM; Khorana A; Matthew Walsh R; Kumar AMS
    J Dig Dis; 2017 Nov; 18(11):642-649. PubMed ID: 29055078
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
    Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Para-aortic node involvement is not an independent predictor of survival after resection for pancreatic cancer.
    Sperti C; Gruppo M; Blandamura S; Valmasoni M; Pozza G; Passuello N; Beltrame V; Moletta L
    World J Gastroenterol; 2017 Jun; 23(24):4399-4406. PubMed ID: 28706422
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Role of Conversion Surgery for Unresectable Pancreatic Cancer After Long-Term Chemotherapy.
    Tsuchiya N; Matsuyama R; Murakami T; Yabushita Y; Sawada Y; Kumamoto T; Endo I
    World J Surg; 2020 Aug; 44(8):2752-2760. PubMed ID: 32291503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.